A synthetic serine protease inhibitor, nafamostat mesilate, is a drug potentially applicable to the treatment of Ebola virus disease

Tohoku Journal of Experimental Medicine

Volumn 237, Issue 1, 2015, Pages 45-50

  Nishimura, Hidekazu ^a   Yamaya, Mutsuo ^b  

^a SENDAI CITY MEDICAL CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cathepsin B; Disseminated intravascular coagulation; Ebola virus disease; Nafamostat mesilate; Surface glycoprotein

Indexed keywords

ANTICOAGULANT AGENT; CATHEPSIN B; CATHEPSIN L; ELECTROLYTE; INFUSION FLUID; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; NAFAMSTAT MESILATE; THROMBOSPONDIN; UNCLASSIFIED DRUG; VESICULOVIRUS VECTOR; VIRUS VECTOR; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 7A; GUANIDINE DERIVATIVE; NAFAMSTAT; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANTICOAGULATION; ANTIVIRAL ACTIVITY; ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EXTRACORPOREAL CIRCULATION; HUMAN; HYPERKALEMIA; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); RISK REDUCTION; VESICULOVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG EFFECTS; ENZYMOLOGY; HEMORRHAGIC FEVER, EBOLA; METABOLISM; RAT;

ANIMALS; ANTIVIRAL AGENTS; DISSEMINATED INTRAVASCULAR COAGULATION; EBOLAVIRUS; FACTOR VIIA; GUANIDINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; HYPERKALEMIA; HYPONATREMIA; RATS; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; VIRUS REPLICATION;

EID: 84940863789     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.237.45     Document Type: Article

References (30)

1. Aoyama, T., Ino, Y., Ozeki, M., Oda, M., Sato, T., Koshiyama, Y., Suzuki, S. & Fujita, M. (1984) Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn. J. Pharmacol., 35, 203-227.
2. Bray, M., Hatfill, S., Hensley, L. & Huggins, J.W. (2001) Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol., 125, 243-253.
3. Centers for Disease Control and Prevention (2015) Ebola virus disease (EVD) information for clinicians in U.S. healthcare settings. http://www.cdc.gov/vhf/ebola/hcp/clinician-information-ushealthcare-settings.html [Accessed: January 30, 2015].
4. Chandran, K., Sullivan, N.J., Felbor, U., Whelan, S.P. & Cunningham, J.M. (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science, 308, 1643-1645.
5. Feldmann, H., Sanchez, A. & Geisbert, T.W. (2013) Filoviridae: Marburg and Ebola viruses. Chapter 32. In Fields Virology, 6th ed., edited by Knipe, D.M. & Howley, P.M. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 923-956.
6. Fujii, S. & Hitomi, Y. (1981) New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta., 661, 342-345.
7. Geisbert, T.W., Hensley, L.E., Jahrling, P.B., Larsen, T., Geisbert, J.B., Paragas, J., Young, H.A., Fredeking, T.M., Rote, W.E. & Vlasuk, G.P. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet, 362, 1953-1958.
8. Hitomi, Y., Ikari, N. & Fujii, S. (1985) Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis, 15, 164-168.
9. Hofmann-Winkler, H., Kaup, F. & Pöhlmann, S. (2012) Host cell factors in filovirus entry: novel players, new insights. Viruses, 4, 3336-3362.
10. Hunt, C.L., Lennemann, N.J. & Maury, W. (2012) Filovirus entry: a novelty in the viral fusion world. Viruses, 4, 258-275.
11. Japanese Society of Hospital Pharmacists (2015) Medical drugs interview form Futhan10 and Futhan5. Medical interview form 4th edition. http://www.torii.co.jp/iyakuDB/data/if/if_fut.pdf [Accessed: July 16, 2015].
12. Koshiyama, Y., Kobori, A., Ogihara, M., Yokomoto, Y., Ohtani, K., Shimamura, K. & Iwaki, M. (1987) The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC). Nihon Yakurigaku Zasshi, 90, 313-320 (in Japanese, abstract in English).
13. Koshiyama, Y., Ozeki, M., Motoyoshi, A., Fujita, M., Iwaki, M. & Aoyama, T. (1984) Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nihon Yakurigaku Zasshi, 84, 417-428 (in Japanese, abstract in English).
14. Manabe, T., Hirano, T., Imanishi, K., Ando, K., Yotsumoto, F. & Tobe, T. (1992) Protective effect of nafamostat mesilate on cellular and lysosomal fragility of acinar cells in rat cerulein pancreatitis. Int. J. Pancreatol., 12, 167-172.
15. Marzi, A. & Falzarano, D. (2015) An updated Ebola vaccine: immunogenic, but will it protect? Lancet, 385, 2229-2230.
16. Marzi, A., Reinheckel, T. & Feldmann, H. (2012) Cathepsin B & L are not required for ebola virus replication. PLoS. Negl. Trop. Dis., 6, e1923.
17. Mohammadi, D. (2014) First trials for Ebola treatments announced. Lancet, 384, 1883.
18. Muto, S., Imai, M. & Asano, Y. (1994) Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br. J. Pharmacol., 111, 173-178.
19. Nanpo, T., Ohtsuki, T., Jin, Y., Matsunaga, K., Takahashi, M, Shibuya, M., Sasaki, H. & Kurumi, M. (1984) Pharmakokinetic studies of FUT-175 (Nafamostat mesilate) (1) Blood level profiles, tissue distribution, metabolism and excretion in rats after intravenous administration. Kiso to Rinsho, 18, 3971-3992 (in Japanese, abstract in English).
20. Okamoto, K., Takeda, S. & Ohsato, K. (1991) Treatment of disseminated intravascular coagulation with proteinase inhibitor. Nihon Rinsho, 49, 2130-2135 (in Japanese).
21. Pak, K., Shirasu, A., Okino, K., Sako, H., Nakane, Y., Umemura, K., Maeda, S. & Tomoyoshi, T. (1988) Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis. Hinyokika Kiyo, 34, 1077-1081 (in Japanese, abstract in English).
22. Shibata, A., Takahashi, H., Aoki, N., Matsuda, T., Yasunaga, K., Kondoh, M., Matsuda, M., Hattori, A., Kobayashi, N., Ogawa, N., Kawakami, Y., Miyazaki, T., Hirayama, A., Yoshida, Y., Chiba, Y., et al. (1988) Clinical effects of FUT-175 (nafamostat mesilate) on disseminated intravascular coagulation (DIC): multi institutional clinical study. Rinsho to Kenkyu, 65, 921-940 (in Japanese).
23. Shibata, A., Takahashi, H., Hattori, A., Kawakami, Y., Hasegawa, H., Miyazaki, T., Morioka, M., Hirayama, A., Uehara, S., Yoshida, Y., Aihara, M., Chiba, Y., Miura, A., Mamiya, S., Goto, Y., et al. (1987) Clinical effects of nafamostat mesilate (FUT-175) on DIC: multi institutional later phase II clinical study. Rinsho to Kenkyu, 64, 1887-1900 (in Japanese).
24. Takemoto, Y., Tanaka, S., Tanabe, J., Nakamura, Y., Kohama, A. & Shibata, S. (1986) Studies on the effects of primary therapy for DIC following circulatory arrest. Am. J. Hematol., 21, 377-382.
25. Toya, D., Hattori, N. & Sawabu, N. (1984) Effects of FUT-175 on pancreatitis. Kiso to Rinsho, 18, 3006-3012 (in Japanese).
26. Tsukagoshi, S. (2000) Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation. Gan To Kagaku Ryoho, 27, 767-774 (in Japanese, abstract in English).
27. Uchiba, M., Okajima, K., Abe, H., Okabe, H. & Takatsuki, K. (1994) Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb. Res., 74, 155-161.
28. Wong, A.C., Sandesara, R.G., Mulherkar, N., Whelan, S.P. & Chandran, K. (2010) A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J. Virol., 84, 163-175.
29. World Health Organization (2014) Consultation on potential Ebola therapies and vaccines. http://www.who.int/mediacentre/events/meetings/2014/ebolainterventions/ en/ [Accessed: August 7, 2015].
30. Yoshikawa, T., Murakami, M., Furukawa, Y., Kato, H., Takemura, S. & Kondo, M. (1983) Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. Haemostasis, 13, 374-378.